Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Cognitive and Affective Representations of Active Surveillance as a Treatment Option for Low-Risk Prostate Cancer.

Lyons KD, Li HH, Mader EM, Stewart TM, Morley CP, Formica MK, Perrapato SD, Seigne JD, Hyams ES, Irwin BH, Mosher T, Hegel MT.

Am J Mens Health. 2016 Jun 29. pii: 1557988316657041. [Epub ahead of print]

PMID:
27365211
2.

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.

Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM.

J Urol. 2016 Jun 16. pii: S0022-5347(16)30629-2. doi: 10.1016/j.juro.2016.06.049. [Epub ahead of print]

PMID:
27317986
3.

A single-centre experience with tumour tract seeding associated with needle manipulation of renal cell carcinomas.

Viswanathan A, Ingimarsson JP, Seigne JD, Schned AR.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E890-3. doi: 10.5489/cuaj.3278. Epub 2015 Dec 14.

4.

MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer.

Armstrong DA, Green BB, Seigne JD, Schned AR, Marsit CJ.

Mol Cancer. 2015 Nov 14;14:194. doi: 10.1186/s12943-015-0466-2.

5.

Robot-assisted partial nephrectomy.

Hyams ES, Seigne JD.

Health Aff (Millwood). 2015 May;34(5):881. doi: 10.1377/hlthaff.2015.0275. No abstract available.

PMID:
25941292
6.

Immunoglobulin G4-related disease in the urinary bladder.

Dropkin BM, Ingimarsson JP, Jones JD, Pettus JR, Seigne JD.

Int J Urol. 2015 Jun;22(6):605-7. doi: 10.1111/iju.12769. Epub 2015 Mar 31.

7.

Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence.

Andrew AS, Marsit CJ, Schned AR, Seigne JD, Kelsey KT, Moore JH, Perreard L, Karagas MR, Sempere LF.

Int J Cancer. 2015 Sep 1;137(5):1158-66. doi: 10.1002/ijc.29413. Epub 2015 Feb 25.

PMID:
25556547
8.

Reply by the authors.

Jarow J, Kluetz PG, Lerner SP, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B.

Urology. 2014 Aug;84(2):495-6. doi: 10.1016/j.urology.2014.04.004. No abstract available.

PMID:
25065996
9.

Cancer-free survival and local tumor control after impendence-based radiofrequency ablation of biopsy-proven renal cell carcinomas with a minimum of 1-year follow-up.

Forauer AR, Dewey BJ, Seigne JD.

Urol Oncol. 2014 Aug;32(6):869-76. doi: 10.1016/j.urolonc.2014.03.016. Epub 2014 Jun 16.

PMID:
24946958
10.

Clinicopathological correlates of Gli1 expression in a population-based cohort of patients with newly diagnosed bladder cancer.

Sverrisson EF, Zens MS, Fei DL, Andrews A, Schned A, Robbins D, Kelsey KT, Li H, DiRenzo J, Karagas MR, Seigne JD.

Urol Oncol. 2014 Jul;32(5):539-45. doi: 10.1016/j.urolonc.2014.03.006. Epub 2014 May 22.

11.

Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop.

Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, Chang S, Dinney CP, Groshen S, Morton RA, O'Donnell M, Quale DZ, Schoenberg M, Seigne J, Vikram B.

Urology. 2014 Feb;83(2):262-4. doi: 10.1016/j.urology.2013.10.030. Epub 2013 Dec 12.

PMID:
24332121
12.

Electrical property sensing biopsy needle for prostate cancer detection.

Mishra V, Schned AR, Hartov A, Heaney JA, Seigne J, Halter RJ.

Prostate. 2013 Nov;73(15):1603-13. doi: 10.1002/pros.22695. Epub 2013 Sep 2.

PMID:
23996675
13.

Transrectal electrical impedance tomography of the prostate: spatially coregistered pathological findings for prostate cancer detection.

Wan Y, Borsic A, Heaney J, Seigne J, Schned A, Baker M, Wason S, Hartov A, Halter R.

Med Phys. 2013 Jun;40(6):063102. doi: 10.1118/1.4803498.

14.

The conundrum of prostatic urethral involvement.

Ingimarsson JP, Seigne JD.

Urol Clin North Am. 2013 May;40(2):249-59. doi: 10.1016/j.ucl.2013.01.010. Epub 2013 Feb 13.

PMID:
23540782
15.

Ureteroscopic biopsy of upper tract urothelial carcinoma using a novel ureteroscopic biopsy forceps.

Wason SE, Seigne JD, Schned AR, Pais VM Jr.

Can J Urol. 2012 Dec;19(6):6560-5.

PMID:
23228292
16.

Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy.

Schwarzer A, Wolf B, Fisher JL, Schwaab T, Olek S, Baron U, Tomlinson CR, Seigne JD, Crosby NA, Gui J, Hampton TH, Fadul CE, Heaney JA, Ernstoff MS.

PLoS One. 2012;7(10):e46600. doi: 10.1371/journal.pone.0046600. Epub 2012 Oct 31.

17.

Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.

Finkelstein SE, Rodriguez F, Dunn M, Farmello MJ, Smilee R, Janssen W, Kang L, Chuang T, Seigne J, Pow-Sang J, Torres-Roca JF, Heysek R, Biagoli M, Shankar R, Scott J, Antonia S, Gabrilovich D, Fishman M.

Immunotherapy. 2012 Apr;4(4):373-82. doi: 10.2217/imt.12.24.

18.

Presence of benign germ cells in a fine needle aspirate of a spermatocele.

Marotti JD, Seigne JD, Gutmann EJ.

Diagn Cytopathol. 2013 Apr;41(4):342-3. doi: 10.1002/dc.21846. Epub 2011 Nov 1. No abstract available.

PMID:
22045691
19.

Stability of serrated gold coil markers in prostate localization.

Gates LL, Gladstone DJ, Kasibhatla MS, Marshall JF, Seigne JD, Hug E, Hartford AC.

J Appl Clin Med Phys. 2011 Apr 18;12(3):3453.

PMID:
21844856
20.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators.

N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk